Heat Biologics Inc (NASDAQ:HTBX) saw a significant increase in short interest in August. As of August 31st, there was short interest totalling 524,800 shares, an increase of 43.2% from the July 31st total of 366,600 shares. Currently, 1.6% of the shares of the company are sold short. Based on an average daily volume of 340,900 shares, the days-to-cover ratio is presently 1.5 days.
HTBX has been the subject of several research reports. Brookline Capital Management initiated coverage on Heat Biologics in a research note on Monday, July 29th. They set a “buy” rating and a $8.00 target price for the company. Alliance Global Partners set a $6.00 target price on Heat Biologics and gave the company a “buy” rating in a research note on Friday, May 17th.
A hedge fund recently raised its stake in Heat Biologics stock. Vanguard Group Inc. boosted its position in shares of Heat Biologics Inc (NASDAQ:HTBX) by 6.8% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,327,660 shares of the biopharmaceutical company’s stock after buying an additional 84,400 shares during the quarter. Vanguard Group Inc. owned 3.90% of Heat Biologics worth $909,000 at the end of the most recent quarter. 5.56% of the stock is currently owned by institutional investors.
HTBX stock traded up $0.02 during trading hours on Friday, hitting $0.58. 16,012 shares of the stock traded hands, compared to its average volume of 415,622. The stock has a 50-day simple moving average of $0.57 and a 200 day simple moving average of $0.87. Heat Biologics has a one year low of $0.46 and a one year high of $2.24. The company has a market cap of $19.66 million, a P/E ratio of -0.64 and a beta of 1.75. The company has a current ratio of 4.50, a quick ratio of 4.50 and a debt-to-equity ratio of 0.01.
Heat Biologics (NASDAQ:HTBX) last announced its earnings results on Wednesday, August 14th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.15) by $0.01. Heat Biologics had a negative return on equity of 75.51% and a negative net margin of 386.16%. The business had revenue of $0.34 million during the quarter, compared to analysts’ expectations of $0.91 million. Analysts forecast that Heat Biologics will post -0.65 earnings per share for the current year.
About Heat Biologics
Heat Biologics, Inc, a biopharmaceutical company, focuses on developing approaches to activate and co-stimulate a patient's immune system against cancer in the United States. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors hot and be administered in combination with checkpoint inhibitors and other immuno-modulators to enhance clinical effectiveness.
Recommended Story: Systematic Risk and Investors
Receive News & Ratings for Heat Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heat Biologics and related companies with MarketBeat.com's FREE daily email newsletter.